NNNN vs STAA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits a stable Piotroski F-Score of 5/9, but this fundamental stability is completely overshadowed by an extreme valuation disconnect. With a Graham Number of $1.46 and an Intrinsic Value of $1.05, the current price of $28.84 represents a massive speculative premium. While profitability margins and revenue growth are exceptional, the Price-to-Sales ratio of 146.39 and P/E of 192.27 are unsustainable. Combined with a bearish technical trend (0/100) and weak insider sentiment, the stock appears to be in a bubble phase.
STAA exhibits severe fundamental weakness as evidenced by a critical Piotroski F-Score of 1/9, indicating a significant deterioration in financial health. While the company maintains a strong liquidity position (Current Ratio 4.55) and impressive gross margins (76.19%), it is unable to translate revenue growth into profitability, with a profit margin of -33.60%. The stock is currently trading at $25.08, which is a premium to the analyst target price of $21.11. Despite a favorable PEG ratio of 0.76, the lack of earnings stability and a bearish technical trend outweigh the growth potential.
Compare Another Pair
Related Comparisons
NNNN vs STAA: Head-to-Head Comparison
This page compares Anbio Biotechnology (NNNN) and STAAR Surgical Company (STAA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.